Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

AmpC

  • Emergence of Resistance in <em>Klebsiella aerogenes</em> to Piperacillin-Tazobactam and Ceftriaxone
    Susceptibility
    Emergence of Resistance in Klebsiella aerogenes to Piperacillin-Tazobactam and Ceftriaxone

    We examined the effects of piperacillin-tazobactam (TZP) concentration and bacterial inoculum on in vitro killing and the emergence of resistance in Klebsiella aerogenes. The MICs for 15 clinical respiratory isolates were determined by broth microdilution for TZP and by Etest for ceftriaxone (CRO) and cefepime (FEP). The presence of resistance in TZP-...

    Marco M. Custodio, Daniel Sanchez, Beverly Anderson, Keenan L. Ryan, Carla Walraven, Renee-Claude Mercier
  • Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing <em>Enterobacterales</em>?: a Systematic Review and Meta-analysis
    Clinical Therapeutics
    Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Enterobacterales?: a Systematic Review and Meta-analysis

    Carbapenem-sparing regimens are needed for the treatment of infections caused by extended-spectrum-β-lactamase (ESBL)- and AmpC-producing members of the Enterobacterales. We sought to compare the clinical efficacy of ceftazidime/avibactam and carbapenems against ESBL- and AmpC-producing Enterobacterales species. A systematic review and meta-analysis of randomized controlled trials comparing ceftazidime/avibactam with...

    Burcu Isler, Yukiko Ezure, Jose Luis García-Fogeda Romero, Patrick Harris, Adam G. Stewart, David L. Paterson
  • <span class="named-content genus-species" id="named-content-1">Escherichia coli</span> Sequence Type 457 Is an Emerging Extended-Spectrum-β-Lactam-Resistant Lineage with Reservoirs in Wildlife and Food-Producing Animals
    Epidemiology and Surveillance
    Escherichia coli Sequence Type 457 Is an Emerging Extended-Spectrum-β-Lactam-Resistant Lineage with Reservoirs in Wildlife and Food-Producing Animals

    Silver gulls carry phylogenetically diverse Escherichia coli, including globally dominant extraintestinal pathogenic E. coli (ExPEC) sequence types and pandemic ExPEC-ST131 clades; however, our large-scale study (504 samples) on silver gulls nesting off the coast of New South Wales identified...

    Kristina Nesporova, Ethan R. Wyrsch, Adam Valcek, Ibrahim Bitar, Khin Chaw, Patrick Harris, Jaroslav Hrabak, Ivan Literak, Steven P. Djordjevic, Monika Dolejska
  • Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> To Accelerate Cephalosporin Hydrolysis and Evade Avibactam
    Editor's Pick Mechanisms of Resistance
    Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam

    Pseudomonas aeruginosa is a leading cause of nosocomial infections worldwide and notorious for its broad-spectrum resistance to antibiotics. A key mechanism that provides extensive resistance to β-lactam antibiotics is the inducible expression of AmpC β-lactamase. Recently, a number of clinical isolates expressing mutated forms of AmpC have been found to be clinically...

    Cole L. Slater, Judith Winogrodzki, Pablo A. Fraile-Ribot, Antonio Oliver, Mazdak Khajehpour, Brian L. Mark
  • Ceftazidime-Avibactam Resistance Mediated by the N<sup>346</sup>Y Substitution in Various AmpC β-Lactamases
    Mechanisms of Resistance
    Ceftazidime-Avibactam Resistance Mediated by the N346Y Substitution in Various AmpC β-Lactamases

    Chromosomal and plasmid-borne AmpC cephalosporinases are a major resistance mechanism to β-lactams in Enterobacteriaceae and Pseudomonas aeruginosa. The new β-lactamase inhibitor avibactam effectively inhibits class C enzymes and can fully restore ceftazidime susceptibility. The conserved amino acid residue Asn346 of AmpC cephalosporinases directly...

    Fabrice Compain, Agathe Debray, Pauline Adjadj, Delphine Dorchêne, Michel Arthur
  • Hypermutator <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients
    Mechanisms of Resistance
    Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients

    Pseudomonas aeruginosa exploits intrinsic and acquired resistance mechanisms to resist almost every antibiotic used in chemotherapy. Antimicrobial resistance in P. aeruginosa isolates recovered from cystic fibrosis (CF) patients is further enhanced by the occurrence of hypermutator strains, a...

    C. A. Colque, A. G. Albarracín Orio, S. Feliziani, R. L. Marvig, A. R. Tobares, H. K. Johansen, S. Molin, A. M. Smania
  • Free
    A Standard Numbering Scheme for Class C β-Lactamases
    Editor's Pick Mechanisms of Resistance
    A Standard Numbering Scheme for Class C β-Lactamases

    Unlike for classes A and B, a standardized amino acid numbering scheme has not been proposed for the class C (AmpC) β-lactamases, which complicates communication in the field. Here, we propose a scheme developed through a collaborative approach that considers both sequence and structure, preserves traditional numbering of catalytically important residues (Ser64, Lys67, Tyr150, and Lys315), is...

    Andrew R. Mack, Melissa D. Barnes, Magdalena A. Taracila, Andrea M. Hujer, Kristine M. Hujer, Gabriel Cabot, Michael Feldgarden, Daniel H. Haft, William Klimke, Focco van den Akker, Alejandro J. Vila, Andrea Smania, Shozeb Haider, Krisztina M. Papp-Wallace, Patricia A. Bradford, Gian Maria Rossolini, Jean-Denis Docquier, Jean-Marie Frère, Moreno Galleni, Nancy D. Hanson, Antonio Oliver, Patrick Plésiat, Laurent Poirel, Patrice Nordmann, Timothy G. Palzkill, George A. Jacoby, Karen Bush, Robert A. Bonomo
  • Emergence of Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in <em>Pseudomonas aeruginosa</em> Sequence Type 308
    Letter to the Editor
    Emergence of Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308
    Pablo A. Fraile-Ribot, Cristóbal del Rosario-Quintana, Carla López-Causapé, María A. Gomis-Font, Mar Ojeda-Vargas, Antonio Oliver
  • A 2.5-Year Within-Patient Evolution of <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> Isolates with <em>In Vivo</em> Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment
    Editor's Pick Mechanisms of Resistance
    A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment

    Ceftolozane-tazobactam is considered to be a last-resort treatment for infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Although resistance to this antimicrobial has been described in vitro, the development of resistance in vivo has rarely been reported. Here, we describe the evolution of resistance to ceftolozane-tazobactam of...

    Thibaud Boulant, Agnès B. Jousset, Rémy A. Bonnin, Aurélie Barrail-Tran, Adrien Borgel, Saoussen Oueslati, Thierry Naas, Laurent Dortet
  • First Clinical Case of <em>In Vivo</em> Acquisition of DHA-1 Plasmid-Mediated AmpC in a <span class="named-content genus-species" id="named-content-1">Salmonella enterica</span> subsp. <em>enterica</em> Isolate
    Mechanisms of Resistance
    First Clinical Case of In Vivo Acquisition of DHA-1 Plasmid-Mediated AmpC in a Salmonella enterica subsp. enterica Isolate

    A pan-susceptible Salmonella enterica serovar Worthington isolate was detected in the stool of a man returning from Sri Lanka. Under ceftriaxone treatment, a third-generation cephalosporin (3GC)-resistant Salmonella Worthington was isolated after 8 days. Molecular analyses indicated that the two isolates were identical. However, the latter strain acquired a...

    Mathieu Clément, Peter M. Keller, Odette J. Bernasconi, Guido Stirnimann, Pascal M. Frey, Guido V. Bloemberg, Parham Sendi, Andrea Endimiani

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596